Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study
Open Forum Infectious Diseases · 29.08.2025 · 12 (9)
DOI: 10.1093/ofid/ofaf553 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 02.09.2025. Verfasst von Raymond N Kuo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei City, Taiwan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, National Science and Technology Council.
Abstract (Originalsprache)
Background
Real-world data evaluating the effectiveness of nirmatrelvir–ritonavir across diverse age groups and vaccination statuses remain limited, particularly in East Asian populations. This study evaluates its effectiveness in reducing severe COVID-19 outcomes using a large, comprehensive nationwide healthcare database and to provide new evidence.
Method
This retrospective observational cohort study involved outpatient COVID-19 patients diagnosed between 1 January 2022, and 1 December 2022, within Taiwan's National Health Insurance Research Database. Patients who received nirmatrelvir–ritonavir were compared with untreated patients. Primary outcomes include COVID-19-related hospitalization, ICU admission, invasive ventilatory support, death, and the composite outcome of hospital admission or death.
Results
A total of 2 300 131 nonhospitalized patients with confirmed COVID-19 between 1 January 2022 and 1 December 2022, including 530 807 patients treated with nirmatrelvir–ritonavir and 1 769 324 untreated patients. Treatment with nirmatrelvir–ritonavir was associated with a significantly lower risk of COVID-19-related hospitalization (hazard ratio 0.32 [95% CI .31–.34]), ICU admission (0.41 [.38–.45]), invasive ventilatory support (0.38 [.33–.43]), death (0.42 [.40–.45]), and the composite outcome of hospital admission or death (0.34 [.33–.35]). Effectiveness was consistent across subgroups stratified by age and vaccination status, with the greatest benefit observed in unvaccinated individuals and those aged ≥65 years with additional risk factors.
Conclusions
In a large, nationally representative cohort, outpatient use of nirmatrelvir–ritonavir was associated with a significantly lower risk of severe COVID-19-related outcomes, regardless of age or vaccination status. These findings reinforce the clinical value of early antiviral treatment, particularly in aging and unvaccinated populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei City, Taiwan.
- Population Health Research Center, National Taiwan University, Taipei City, Taiwan.
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan.
- Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei City, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
- Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan.
ORCID-Profile: Raymond N Kuo, Wen-Yi Shau, Shan-Chwen Chang
Förderung
- Pfizer
- National Science and Technology Council
Zitieren
APA
Kuo, R. N., Chen, W., Shau, W. Y., & Chang, S. C. (2025). Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study. Open Forum Infectious Diseases, 12(9). https://doi.org/10.1093/ofid/ofaf553
Vancouver
Kuo RN, Chen W, Shau WY, Chang SC. Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study. Open Forum Infectious Diseases. 2025;12(9). doi:10.1093/ofid/ofaf553
BibTeX
@article{Kuo2025,
author = {Kuo, Raymond N and Chen, Wanchi and Shau, Wen-Yi and Chang, Shan-Chwen},
title = {Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {9},
doi = {10.1093/ofid/ofaf553}
}
EUVIMED